As expected, the addition of rituximab at day 30 resulted in a rapid decrease in ALC values in CD49d− CLL, which became superimposable to those of CD49d+ CLL at later time points (Fig. S2 A). Here, ITGA4 is linked to B-cell chronic lymphocytic leukemia.